EverQuote, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EverQuote, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $97.29M | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | $89.98M | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | $78.30M | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | $81.36M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | $73.80M | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | $67.11M | Mar 1, 2021 |
| FY2020 | Jun 30, 2019 | $55.67M | Mar 1, 2021 |
| FY2020 | Mar 31, 2019 | $52.23M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $39.78M | Mar 13, 2020 |
| FY2019 | Sep 30, 2018 | $41.75M | Mar 13, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $692.52M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $500.19M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $287.92M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $404.13M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $418.52M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $346.94M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $248.81M | Feb 25, 2022 |
| FY2019 | Dec 31, 2018 | $163.35M | Mar 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.31M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $32.17M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($51.29M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($24.42M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($19.43M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($3.77M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($3.18M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($2.81M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($1.44M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($934.0K) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.34M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $31.75M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($51.98M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($24.79M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($21.92M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($3.78M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($3.29M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($2.96M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($1.65M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($1.16M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $29.55M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $27.59M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $31.71M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $35.73M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $29.66M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $20.21M | Feb 25, 2022 |
| FY2019 | Dec 31, 2018 | $14.17M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $9.19M | Apr 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.38M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $66.57M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($2.83M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($15.79M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $7.19M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $10.67M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $4.41M | Feb 25, 2022 |
| FY2019 | Dec 31, 2018 | ($1.90M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($1.67M) | Apr 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $326.91M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $210.53M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $110.93M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $156.52M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $143.61M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $129.05M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $91.22M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $65.75M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $20.52M | Apr 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.87M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $75.16M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $30.02M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $49.03M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $58.48M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $58.07M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $39.45M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $22.56M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $20.13M | Apr 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.04M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $135.37M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $80.91M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $107.49M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $85.13M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $70.98M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $51.77M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $43.18M | Feb 25, 2022 |
| FY2019 | Dec 31, 2017 | ($50.54M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($25.66M) | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $21.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $21.50M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $21.50M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $21.50M | Feb 27, 2023 |
| FY2022 | Dec 31, 2020 | $9.79M | Feb 27, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.87M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($181.18M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($213.35M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($162.06M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($137.65M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($118.21M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($107.01M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($99.89M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($51.32M) | Apr 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.38M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $102.12M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $37.96M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $30.84M | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $34.85M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $42.87M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $46.05M | Feb 25, 2022 |
| FY2019 | Dec 31, 2018 | $41.63M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.36M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 25, 2022 |